Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of “Agreement Letter” for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease
- Thursday, February 6, 2020, 7:03
- Finance
- Add a comment
CARMIEL, Israel, Feb. 6, 2020 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant…
About the Author
adminasapcorp has written 41552 stories on this site.